Inferra AI / Company / BCRX
Biocryst Pharmaceuticals Inc.
BCRX · Health Care
Last earnings Aug 5, 2026
Key results
Revenuequarter
$156.8 million
revenue of $156.8 million (+45 percent y-o-y) Q2 2025 operating profit of $29.8 million (+239 percent y-o-y)
SEC original ↗Biocryst Pharmaceuticals Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
ORLADEYO (berotralstat): Oral, Once-daily Treatment for Prevention of Hereditary Angioedema (HAE) Attacks ORLADEYO net revenue in the second quarter of 2025 was $156.8 million (+45 percent year-over-year (y-o-y)).
SEC original ↗Biocryst Pharmaceuticals Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
Second Quarter 2025 Financial Results For the three months ended June 30, 2025, total revenues were $163.4 million, compared to $109.3 million in the second quarter of 2024 (+50 percent y-o-y).
SEC original ↗Biocryst Pharmaceuticals Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
The increase was primarily due to $156.8 million in ORLADEYO net revenue in the second quarter of 2025, compared to $108.3 million in ORLADEYO net revenue in the second quarter of 2024 (+45 percent y-o-y).
SEC original ↗Biocryst Pharmaceuticals Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
Operating incomequarter
$29.8 million
Operating income for the second quarter of 2025 was $29.8 million, compared to $8.8 million for the second quarter of 2024.
SEC original ↗Biocryst Pharmaceuticals Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
Net incomequarter
$5.1 million
Net income for the second quarter of 2025 was $5.1 million, or $0.02 per share, compared to a net loss of $12.7 million, or $0.06 per share, for the second quarter of 2024.
SEC original ↗Biocryst Pharmaceuticals Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
AI analysis
Q2 2025 · reported Aug 4, 2025
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
The quarter in charts
Guidance ladder — revenue
Delivered vs the company's guided range
EX-99 · Aug 4, 2025 Guide as stated by the company; range and midpoint computed from the stated figure.
Headline figures
| Metric | Q2 2025 | Prior qtr | Year ago |
|---|---|---|---|
| Revenue | $156.8 million | — | — |
| Operating income | $29.8 million | — | $8.8 million |
| Net income | $5.1 million | — | — |
Guidance · company-stated
Direction: Reiterated
“Financial Outlook for 2025 The company is maintaining its outlook for full year 2025 global net ORLADEYO revenue to between $580 million and $600 million, even when excluding fourth quarter European revenue after the expected closing of the sale of its European business.”
Classified from the release's primary full-year outlook statement.
Capital allocation
htm PRESS RELEASE EdgarFiling EXHIBIT 99.1 BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update Q2 2025 ORLADEYO net revenue of $156.8 million (+45 percent y-o-y) Q2 2025 operating profit of $29.8 million (+239 percent y-o-y); non-GAAP operating profit of $57.0 million (+160 percent y-o-y) Company makes additional $50 million paydown of term debt and plans to retire all remaining term debt with proceeds of sale of European ORLADEYO business RESEARCH TRIANGLE PARK, N.
What changed vs last quarter
- Guide midpoint vs latest-quarter revenue +269.9% computed from stated figures
Event summary
Biocryst Pharmaceuticals Inc. Q2 2025 — revenue of $156.8 million (+45 percent y-o-y) Q2 2025 operating profit of $29.8 million (+239 percent y-o-y)
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
Direction: Reiterated
Revenue: “Financial Outlook for 2025 The company is maintaining its outlook for full year 2025 global net ORLADEYO revenue to between $580 million and $600 million, even when excluding fourth quarter European revenue after the expected closing of the sale of its European business.”
Revenue — Reiterated (“maintaining”)
“Financial Outlook for 2025 The company is maintaining its outlook for full year 2025 global net ORLADEYO revenue to between $580 million and $600 million, even when excluding fourth quarter European revenue after the expected closing of the sale of its European business.”
Classified from the release's primary full-year outlook statement.
Capital allocation
htm PRESS RELEASE EdgarFiling EXHIBIT 99.1 BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update Q2 2025 ORLADEYO net revenue of $156.8 million (+45 percent y-o-y) Q2 2025 operating profit of $29.8 million (+239 percent y-o-y); non-GAAP operating profit of $57.0 million (+160 percent y-o-y) Company makes additional $50 million paydown of term debt and plans to retire all remaining term debt with proceeds of sale of European ORLADEYO business RESEARCH TRIANGLE PARK, N.
SEC original ↗Biocryst Pharmaceuticals Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
The decrease was primarily the result of the $75 million partial prepayment on the outstanding principal amount under the Pharmakon Term Loan in April 2025, and the decrease in the effective interest rate related to the Pharmakon Loan Agreement.
SEC original ↗Biocryst Pharmaceuticals Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
In July, the company paid down an additional $50 million on the outstanding principal amount under the Pharmakon term loan, leaving a remaining principal balance of $199 million.
SEC original ↗Biocryst Pharmaceuticals Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
Upon the expected closing of the sale of its European business in early October, the company intends to retire all its remaining term debt.
SEC original ↗Biocryst Pharmaceuticals Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
The Company may, in the future, issue securities, including common stock, preferred stock, depositary shares, purchase contracts, warrants, debt securities and units, through private placement transactions or registered public offerings.
SEC original ↗Biocryst Pharmaceuticals Inc. — 10-Q Quarterly report10-QAug 5, 2026
In accordance with its policy, the Company is able to invest in marketable debt securities that may consist of U.
SEC original ↗Biocryst Pharmaceuticals Inc. — 10-Q Quarterly report10-QAug 5, 2026
Strategy & priorities
Statements that describe our future plans, strategies, intentions, expectations, objectives, goals or prospects are also forward-looking statements.
SEC original ↗Biocryst Pharmaceuticals Inc. — 10-Q Quarterly report10-QAug 5, 2026
For example, applicable regulatory agencies could refuse to approve, or impose restrictions or warnings on, our product candidates, require us to conduct additional studies or adopt study designs that differ from our planned development strategies, suspend or terminate our clinical trials, withdraw approval for our products, or take other actions that could materially impact the cost, timing, and success of our planned development and commercialization strategies.
SEC original ↗Biocryst Pharmaceuticals Inc. — 10-Q Quarterly report10-QAug 5, 2026
There can be no assurance that our or our partners commercialization efforts, methods, and strategies for our products or technologies will succeed, and our future revenue generation is uncertain.
SEC original ↗Biocryst Pharmaceuticals Inc. — 10-Q Quarterly report10-QAug 5, 2026
In addition, we and our partners may be subject to new legislation, regulatory proposals, and healthcare payor initiatives that may increase our costs of compliance and adversely affect our or our partners ability to market our products or develop our product candidates.
SEC original ↗Biocryst Pharmaceuticals Inc. — 10-Q Quarterly report10-QAug 5, 2026
International expansion of our business exposes us to business, legal, regulatory, political, operational, financial, and economic risks.
SEC original ↗Biocryst Pharmaceuticals Inc. — 10-Q Quarterly report10-QAug 5, 2026
Risks & headwinds
These statements involve known and unknown risks, uncertainties and other factors which may cause BioCryst s actual results, performance, achievements or pipeline development timing to be materially different from any future results, performance, achievements, or timing expressed or implied by the forward-looking statements.
SEC original ↗Biocryst Pharmaceuticals Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
These statements reflect our current views with respect to future events and are based on assumptions, including assumptions related to the expected date of closing of the Transaction and the potential benefits thereof, and are subject to risks and uncertainties.
SEC original ↗Biocryst Pharmaceuticals Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
Given these uncertainties, you should not place undue reliance on these forward-looking statements.
SEC original ↗Biocryst Pharmaceuticals Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
Legal Proceedings 49 Item 1A.
SEC original ↗Biocryst Pharmaceuticals Inc. — 10-Q Quarterly report10-QAug 5, 2026
While we believe these expectations are reasonable, forward-looking statements are inherently subject to known and unknown risks and uncertainties, many of which are beyond our control.
SEC original ↗Biocryst Pharmaceuticals Inc. — 10-Q Quarterly report10-QAug 5, 2026
Any forward-looking statement is subject to these and other risks, uncertainties, and assumptions relating to our operations, results of operations, industry, and future growth.
SEC original ↗Biocryst Pharmaceuticals Inc. — 10-Q Quarterly report10-QAug 5, 2026
Earnings deck slides
0 decks with slide viewBiocryst Pharmaceuticals Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
33 documentsEarnings releases
7 documentsPresentations
1 document- Q3 2025
- BCRXDeck
Transcripts
0 documentsNo transcripts for Biocryst Pharmaceuticals Inc. are held in this edition of the library.
See also the earnings calendar for every tracked company’s next earnings date.